MASH cirrhosis treatment, fibrosis reversal, and population screening were cited by experts as hepatology's biggest gaps.
Mazen Noureddin, MD, MHSc
Advertisement
Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist Hospital.
Articles by Mazen Noureddin, MD, MHSc
Phase 2 data for DD01 and pemvidutide show liver-directed MASH benefits beyond weight loss, with strong tolerability heading into phase 3.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol
3
Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL
4
HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD
5